

Ernesto Mejías-Páez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4889406/publications.pdf>

Version: 2024-02-01

16
papers

948
citations

759233

12
h-index

940533

16
g-index

17
all docs

17
docs citations

17
times ranked

1615
citing authors

#	ARTICLE	IF	CITATIONS
1	Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8+ T cells. <i>Nature Communications</i> , 2017, 8, 16073.	12.8	222
2	Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. <i>Nature Medicine</i> , 2022, 28, 496-503.	30.7	215
3	The Evolution of Poxvirus Vaccines. <i>Viruses</i> , 2015, 7, 1726-1803.	3.3	164
4	MicroRNAs are minor constituents of extracellular vesicles that are rarely delivered to target cells. <i>PLoS Genetics</i> , 2021, 17, e1009951.	3.5	125
5	Distinct Roles of Vaccinia Virus NF- κ B Inhibitor Proteins A52, B15, and K7 in the Immune Response. <i>Journal of Virology</i> , 2017, 91, .	3.4	31
6	High Quality Long-Term CD4+ and CD8+ Effector Memory Populations Stimulated by DNA-LACK/MVA-LACK Regimen in <i>Leishmania major</i> BALB/c Model of Infection. <i>PLoS ONE</i> , 2012, 7, e38859.	2.5	30
7	Virological and Immunological Characterization of Novel NYVAC-Based HIV/AIDS Vaccine Candidates Expressing Clade C Trimeric Soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as Virus-Like Particles. <i>Journal of Virology</i> , 2015, 89, 970-988.	3.4	30
8	NF κ B activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1333-E1342.	7.1	26
9	New vaccinia virus promoter as a potential candidate for future vaccines. <i>Journal of General Virology</i> , 2013, 94, 2771-2776.	2.9	22
10	Development of a Safe and Effective Vaccinia Virus Oncolytic Vector WR- $\hat{1}$ 4 with a Set of Gene Deletions on Several Viral Pathways. <i>Molecular Therapy - Oncolytics</i> , 2018, 8, 27-40.	4.4	22
11	Attenuated and Replication-Competent Vaccinia Virus Strains M65 and M101 with Distinct Biology and Immunogenicity as Potential Vaccine Candidates against Pathogens. <i>Journal of Virology</i> , 2013, 87, 6955-6974.	3.4	14
12	Modification of promoter spacer length in vaccinia virus as a strategy to control the antigen expression. <i>Journal of General Virology</i> , 2015, 96, 2360-2371.	2.9	14
13	Rapid, efficient and activation-neutral gene editing of polyclonal primary human resting CD4+ T cells allows complex functional analyses. <i>Nature Methods</i> , 2022, 19, 81-89.	19.0	12
14	A Prime/Boost PfCS14K ^M /MVA-sPfCS ^M Vaccination Protocol Generates Robust CD8 ⁺ T Cell and Antibody Responses to <i>Plasmodium falciparum</i> Circumsporozoite Protein and Protects Mice against Malaria. <i>Vaccine Journal</i> , 2017, 24, .	3.1	10
15	Neutrophil subtypes shape HIV-specific CD8 T-cell responses after vaccinia virus infection. <i>Npj Vaccines</i> , 2021, 6, 52.	6.0	6
16	The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1. <i>Frontiers in Immunology</i> , 2019, 10, 2793.	4.8	2